Future Applications of and Prospects for Near-IR Photoimmunotherapy: Benefits and Differences Compared with Photodynamic and Photothermal Therapy

ImmunotherapyVol. 13, No. 16 EditorialFuture applications of and prospects for near-IR photoimmunotherapy: benefits and differences compared with photodynamic and photothermal therapyHisataka Kobayashi & Peter L ChoykeHisataka Kobayashi *Author for correspondence: Tel.: +1 240 858 3069; E-mail Address: kobayash@mail.nih.govhttps://orcid.org/0000-0003-1019-4112Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USASearch for more papers by this author & Peter L Choyke https://orcid.org/0000-0003-1086-8826Molecular Imaging Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USASearch for more papers by this authorPublished Online:13 Sep 2021https://doi.org/10.2217/imt-2021-0216AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: antibody therapeuticscancer immunologymolecular immunologyReferences1. Kobayashi H, Choyke PL. Near-infrared photoimmunotherapy of cancer. Acc. Chem. Res. 52(8), 2332–2339 (2019).Crossref, Medline, CAS, Google Scholar2. Kobayashi H, Griffiths GL, Choyke PL. Near-infrared photoimmunotherapy: photoactivatable antibody-drug conjugates (ADCs). Bioconjug. Chem. 31(1), 28–36 (2020).Crossref, Medline, CAS, Google Scholar3. Mitsunaga M, Ogawa M, Kosaka N, Rosenblum LT, Choyke PL, Kobayashi H. Cancer cell-selective in vivo near infrared photoimmunotherapy targeting specific membrane molecules. Nat. Med. 17(12), 1685–1691 (2011).Crossref, Medline, CAS, Google Scholar4. ClinicalTrials ASP-1929 photoimmunotherapy (PIT) study in recurrent head/neck cancer for patients who have failed at least two lines of therapy (2021). https://clinicaltrials.gov/ct2/show/NCT03769506Google Scholar5. Sato K, Ando K, Okuyama S et al. Photoinduced ligand release from a silicon phthalocyanine dye conjugated with monoclonal antibodies: a mechanism of cancer cell cytotoxicity after near-infrared photoimmunotherapy. ACS Cent. Sci. 4(11), 1559–1569 (2018).Crossref, Medline, CAS, Google Scholar6. Ogawa M, Tomita Y, Nakamura Y et al. Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. Oncotarget 8(6), 10425–10436 (2017).Crossref, Medline, Google Scholar7. Nagaya T, Friedman J, Maruoka Y et al. Host immunity following near-infrared photoimmunotherapy is enhanced with PD-1 checkpoint blockade to eradicate established antigenic tumors. Cancer Immunol. Res. 7(3), 401–413 (2019).Crossref, Medline, CAS, Google Scholar8. Okada R, Kato T, Furusawa A et al. Local depletion of immune checkpoint ligand CTLA4 expressing cells in tumor beds enhances antitumor host immunity. Adv. Ther. (Weinh.) 4(5), 2000269 (2021).Crossref, Medline, CAS, Google Scholar9. Sato K, Sato N, Xu B et al. Spatially selective depletion of tumor-associated regulatory T cells with near-infrared photoimmunotherapy. Sci. Transl. Med. 8(352), 352ra110 (2016).Crossref, Medline, Google Scholar10. Kato T, Wakiyama H, Furusawa A, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy; a review of targets for cancer therapy. Cancers (Basel) 13(11), 2535 (2021).Crossref, Medline, Google Scholar11. Nagaya T, Okuyama S, Ogata F, Maruoka Y, Choyke PL, Kobayashi H. Endoscopic near infrared photoimmunotherapy using a fiber optic diffuser for peritoneal dissemination of gastric cancer. Cancer Sci. 109(6), 1902–1908 (2018).Crossref, Medline, CAS, Google Scholar12. Sato K, Nagaya T, Mitsunaga M, Choyke PL, Kobayashi H. Near infrared photoimmunotherapy for lung metastases. Cancer Lett. 365(1), 112–121 (2015).Crossref, Medline, CAS, Google Scholar13. Sano K, Nakajima T, Choyke PL, Kobayashi H. Markedly enhanced permeability and retention effects induced by photo-immunotherapy of tumors. ACS Nano 7(1), 717–724 (2013).Crossref, Medline, CAS, Google Scholar14. Mitsunaga M, Nakajima T, Sano K, Choyke PL, Kobayashi H. Near-infrared theranostic photoimmunotherapy (PIT): repeated exposure of light enhances the effect of immunoconjugate. Bioconjug. Chem. 23(3), 604–609 (2012).Crossref, Medline, Google Scholar15. Maruoka Y, Furusawa A, Okada R et al. Combined CD44- and CD25-targeted near-infrared photoimmunotherapy selectively kills cancer and regulatory T cells in syngeneic mouse cancer models. Cancer Immunol. Res. 8(3), 345–355 (2020).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByTrastuzumab‐based near‐infrared photoimmunotherapy in xenograft mouse of breast cancer18 October 2022 | Cancer Medicine, Vol. 12, No. 4 Vol. 13, No. 16 Follow us on social media for the latest updates Metrics Downloaded 108 times History Received 8 August 2021 Accepted 25 August 2021 Published online 13 September 2021 Published in print November 2021 Information© 2021 Future Medicine LtdKeywordsantibody therapeuticscancer immunologymolecular immunologyAuthor contributionsH Kobayashi and PL Choyke contributed equally to this article.Financial & competing interests disclosureThis work was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute, NIH (grant no. ZIA BC 011513). The authors are inventors of US government patents on NIR-PIT that have been licensed to Rakuten Medical Inc. The authors do not receive direct payments from Rakuten Medical Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download